Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis
Summary Objective Visfatin is a newly identified adipocytokine and recent studies indicated that visfatin may have potential proinflammatory effect. However, its pathophysiological role in the metabolic syndrome (MetS) is not fully understood. In this study we investigated whether serum visfatin le...
Gespeichert in:
| Veröffentlicht in: | Clinical endocrinology (Oxford) 2008-12, Vol.69 (6), p.878-884 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 884 |
|---|---|
| container_issue | 6 |
| container_start_page | 878 |
| container_title | Clinical endocrinology (Oxford) |
| container_volume | 69 |
| creator | Zhong, Ming Tan, Hong-wei Gong, Hui-ping Wang, Shu-fang Zhang, Yun Zhang, Wei |
| description | Summary
Objective Visfatin is a newly identified adipocytokine and recent studies indicated that visfatin may have potential proinflammatory effect. However, its pathophysiological role in the metabolic syndrome (MetS) is not fully understood. In this study we investigated whether serum visfatin levels is altered in patients with the MetS, and compared the levels of visfatin between patients with and without carotid plaques.
Design and method A total of 139 patients with MetS and 105 controls were included. The patients were further divided into two groups: 40 with carotid plaques and 99 without carotid plaques. Serum visfatin was measured by using enzyme immunoassay method and carotid intimal‐media thickness (IMT) was measured by ultrasound in all subjects.
Results Serum visfatin was elevated in both MetS patients with and without carotid plaques compared to controls (log visfatin: 1·14 ± 0·14 vs. 0·99 ± 0·17 ng/ml vs. 0·93 ± 0·23 ng/ml, P |
| doi_str_mv | 10.1111/j.1365-2265.2008.03248.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69839363</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69839363</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4358-53317629d6ab5765fa27cca2d399ebd30c7f8ce97a3489bdad0c6710e205ba43</originalsourceid><addsrcrecordid>eNqNkM1v2yAYh9HUac26_QsTl_VmD4P58GGHKkqbala3Q6Xthl4DVsn8kYLTJv_98BJl1yEEr8Tzg5cHIVyQvEjjyyYvmOAZpYLnlBCVE0ZLle_foMX54AItCCMkI0KUl-h9jBtCCFdEvkOXhWKCKcUX6Nf9YIKD6CyOLux6_OJjC5MfcJrbVLhhivjVT0-4dxM0Y-cNjofBhrF3GAaLDYRx8hbD9OTCGE03rz5-QG9b6KL7eNqv0OPt6nG5zurvd_fLmzozJeMq44wVUtDKCmi4FLwFKo0BallVucYyYmSrjKsksFJVjQVLjJAFcZTwBkp2ha6P127D-LxzcdK9j8Z1HQxu3EUtKsWq9NkEqiNoUnsxuFZvg-8hHHRB9CxVb_TsTs_u9CxV_5Wq9yn66fTGrumd_Rc8WUzA5xMA0UDXBhiMj2eOElUKqWjivh65V9-5w383oJerh7lK-eyY93Fy-3Mewm8tJJNc_3y402q9_lHX1Tddsz8Nu6MW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69839363</pqid></control><display><type>article</type><title>Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Zhong, Ming ; Tan, Hong-wei ; Gong, Hui-ping ; Wang, Shu-fang ; Zhang, Yun ; Zhang, Wei</creator><creatorcontrib>Zhong, Ming ; Tan, Hong-wei ; Gong, Hui-ping ; Wang, Shu-fang ; Zhang, Yun ; Zhang, Wei</creatorcontrib><description>Summary
Objective Visfatin is a newly identified adipocytokine and recent studies indicated that visfatin may have potential proinflammatory effect. However, its pathophysiological role in the metabolic syndrome (MetS) is not fully understood. In this study we investigated whether serum visfatin levels is altered in patients with the MetS, and compared the levels of visfatin between patients with and without carotid plaques.
Design and method A total of 139 patients with MetS and 105 controls were included. The patients were further divided into two groups: 40 with carotid plaques and 99 without carotid plaques. Serum visfatin was measured by using enzyme immunoassay method and carotid intimal‐media thickness (IMT) was measured by ultrasound in all subjects.
Results Serum visfatin was elevated in both MetS patients with and without carotid plaques compared to controls (log visfatin: 1·14 ± 0·14 vs. 0·99 ± 0·17 ng/ml vs. 0·93 ± 0·23 ng/ml, P < 0·001 and P < 0·05 vs. control group, respectively), and in patients with carotid plaques more than in patients without carotid plaques (P < 0·001). Multiple stepwise regression analysis revealed that only LDL‐cholesterol correlated with visfatin, and visfatin independently correlated with max IMT in the patients with MetS. A log visfatin > 1·08 ng/ml had 70% sensitivity and 67% specificity for detecting patients with carotid plaques.
Conclusions/interpretation Our results showed that serum visfatin was increased in patients with MetS, especially in those with carotid plaques. Visfatin may be an inflammatory marker of MetS.</description><identifier>ISSN: 0300-0664</identifier><identifier>EISSN: 1365-2265</identifier><identifier>DOI: 10.1111/j.1365-2265.2008.03248.x</identifier><identifier>PMID: 18363885</identifier><identifier>CODEN: CLECAP</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Biological and medical sciences ; Carotid Artery Diseases - blood ; Carotid Artery Diseases - pathology ; Carotid Artery, Common - diagnostic imaging ; Carotid Artery, Common - pathology ; Endocrinopathies ; Female ; Fundamental and applied biological sciences. Psychology ; Humans ; Male ; Medical sciences ; Metabolic diseases ; Metabolic Syndrome - blood ; Middle Aged ; Miscellaneous ; Nicotinamide Phosphoribosyltransferase - blood ; Other metabolic disorders ; Regression Analysis ; Tunica Intima - diagnostic imaging ; Tunica Intima - pathology ; Tunica Media - diagnostic imaging ; Tunica Media - pathology ; Ultrasonography ; Vertebrates: endocrinology</subject><ispartof>Clinical endocrinology (Oxford), 2008-12, Vol.69 (6), p.878-884</ispartof><rights>2008 The Authors. Journal compilation © 2008 Blackwell Publishing Ltd</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4358-53317629d6ab5765fa27cca2d399ebd30c7f8ce97a3489bdad0c6710e205ba43</citedby><cites>FETCH-LOGICAL-c4358-53317629d6ab5765fa27cca2d399ebd30c7f8ce97a3489bdad0c6710e205ba43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2265.2008.03248.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2265.2008.03248.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20846782$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18363885$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhong, Ming</creatorcontrib><creatorcontrib>Tan, Hong-wei</creatorcontrib><creatorcontrib>Gong, Hui-ping</creatorcontrib><creatorcontrib>Wang, Shu-fang</creatorcontrib><creatorcontrib>Zhang, Yun</creatorcontrib><creatorcontrib>Zhang, Wei</creatorcontrib><title>Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis</title><title>Clinical endocrinology (Oxford)</title><addtitle>Clin Endocrinol (Oxf)</addtitle><description>Summary
Objective Visfatin is a newly identified adipocytokine and recent studies indicated that visfatin may have potential proinflammatory effect. However, its pathophysiological role in the metabolic syndrome (MetS) is not fully understood. In this study we investigated whether serum visfatin levels is altered in patients with the MetS, and compared the levels of visfatin between patients with and without carotid plaques.
Design and method A total of 139 patients with MetS and 105 controls were included. The patients were further divided into two groups: 40 with carotid plaques and 99 without carotid plaques. Serum visfatin was measured by using enzyme immunoassay method and carotid intimal‐media thickness (IMT) was measured by ultrasound in all subjects.
Results Serum visfatin was elevated in both MetS patients with and without carotid plaques compared to controls (log visfatin: 1·14 ± 0·14 vs. 0·99 ± 0·17 ng/ml vs. 0·93 ± 0·23 ng/ml, P < 0·001 and P < 0·05 vs. control group, respectively), and in patients with carotid plaques more than in patients without carotid plaques (P < 0·001). Multiple stepwise regression analysis revealed that only LDL‐cholesterol correlated with visfatin, and visfatin independently correlated with max IMT in the patients with MetS. A log visfatin > 1·08 ng/ml had 70% sensitivity and 67% specificity for detecting patients with carotid plaques.
Conclusions/interpretation Our results showed that serum visfatin was increased in patients with MetS, especially in those with carotid plaques. Visfatin may be an inflammatory marker of MetS.</description><subject>Biological and medical sciences</subject><subject>Carotid Artery Diseases - blood</subject><subject>Carotid Artery Diseases - pathology</subject><subject>Carotid Artery, Common - diagnostic imaging</subject><subject>Carotid Artery, Common - pathology</subject><subject>Endocrinopathies</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Metabolic Syndrome - blood</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Nicotinamide Phosphoribosyltransferase - blood</subject><subject>Other metabolic disorders</subject><subject>Regression Analysis</subject><subject>Tunica Intima - diagnostic imaging</subject><subject>Tunica Intima - pathology</subject><subject>Tunica Media - diagnostic imaging</subject><subject>Tunica Media - pathology</subject><subject>Ultrasonography</subject><subject>Vertebrates: endocrinology</subject><issn>0300-0664</issn><issn>1365-2265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkM1v2yAYh9HUac26_QsTl_VmD4P58GGHKkqbala3Q6Xthl4DVsn8kYLTJv_98BJl1yEEr8Tzg5cHIVyQvEjjyyYvmOAZpYLnlBCVE0ZLle_foMX54AItCCMkI0KUl-h9jBtCCFdEvkOXhWKCKcUX6Nf9YIKD6CyOLux6_OJjC5MfcJrbVLhhivjVT0-4dxM0Y-cNjofBhrF3GAaLDYRx8hbD9OTCGE03rz5-QG9b6KL7eNqv0OPt6nG5zurvd_fLmzozJeMq44wVUtDKCmi4FLwFKo0BallVucYyYmSrjKsksFJVjQVLjJAFcZTwBkp2ha6P127D-LxzcdK9j8Z1HQxu3EUtKsWq9NkEqiNoUnsxuFZvg-8hHHRB9CxVb_TsTs_u9CxV_5Wq9yn66fTGrumd_Rc8WUzA5xMA0UDXBhiMj2eOElUKqWjivh65V9-5w383oJerh7lK-eyY93Fy-3Mewm8tJJNc_3y402q9_lHX1Tddsz8Nu6MW</recordid><startdate>200812</startdate><enddate>200812</enddate><creator>Zhong, Ming</creator><creator>Tan, Hong-wei</creator><creator>Gong, Hui-ping</creator><creator>Wang, Shu-fang</creator><creator>Zhang, Yun</creator><creator>Zhang, Wei</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200812</creationdate><title>Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis</title><author>Zhong, Ming ; Tan, Hong-wei ; Gong, Hui-ping ; Wang, Shu-fang ; Zhang, Yun ; Zhang, Wei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4358-53317629d6ab5765fa27cca2d399ebd30c7f8ce97a3489bdad0c6710e205ba43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Biological and medical sciences</topic><topic>Carotid Artery Diseases - blood</topic><topic>Carotid Artery Diseases - pathology</topic><topic>Carotid Artery, Common - diagnostic imaging</topic><topic>Carotid Artery, Common - pathology</topic><topic>Endocrinopathies</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Metabolic Syndrome - blood</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Nicotinamide Phosphoribosyltransferase - blood</topic><topic>Other metabolic disorders</topic><topic>Regression Analysis</topic><topic>Tunica Intima - diagnostic imaging</topic><topic>Tunica Intima - pathology</topic><topic>Tunica Media - diagnostic imaging</topic><topic>Tunica Media - pathology</topic><topic>Ultrasonography</topic><topic>Vertebrates: endocrinology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhong, Ming</creatorcontrib><creatorcontrib>Tan, Hong-wei</creatorcontrib><creatorcontrib>Gong, Hui-ping</creatorcontrib><creatorcontrib>Wang, Shu-fang</creatorcontrib><creatorcontrib>Zhang, Yun</creatorcontrib><creatorcontrib>Zhang, Wei</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical endocrinology (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhong, Ming</au><au>Tan, Hong-wei</au><au>Gong, Hui-ping</au><au>Wang, Shu-fang</au><au>Zhang, Yun</au><au>Zhang, Wei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis</atitle><jtitle>Clinical endocrinology (Oxford)</jtitle><addtitle>Clin Endocrinol (Oxf)</addtitle><date>2008-12</date><risdate>2008</risdate><volume>69</volume><issue>6</issue><spage>878</spage><epage>884</epage><pages>878-884</pages><issn>0300-0664</issn><eissn>1365-2265</eissn><coden>CLECAP</coden><abstract>Summary
Objective Visfatin is a newly identified adipocytokine and recent studies indicated that visfatin may have potential proinflammatory effect. However, its pathophysiological role in the metabolic syndrome (MetS) is not fully understood. In this study we investigated whether serum visfatin levels is altered in patients with the MetS, and compared the levels of visfatin between patients with and without carotid plaques.
Design and method A total of 139 patients with MetS and 105 controls were included. The patients were further divided into two groups: 40 with carotid plaques and 99 without carotid plaques. Serum visfatin was measured by using enzyme immunoassay method and carotid intimal‐media thickness (IMT) was measured by ultrasound in all subjects.
Results Serum visfatin was elevated in both MetS patients with and without carotid plaques compared to controls (log visfatin: 1·14 ± 0·14 vs. 0·99 ± 0·17 ng/ml vs. 0·93 ± 0·23 ng/ml, P < 0·001 and P < 0·05 vs. control group, respectively), and in patients with carotid plaques more than in patients without carotid plaques (P < 0·001). Multiple stepwise regression analysis revealed that only LDL‐cholesterol correlated with visfatin, and visfatin independently correlated with max IMT in the patients with MetS. A log visfatin > 1·08 ng/ml had 70% sensitivity and 67% specificity for detecting patients with carotid plaques.
Conclusions/interpretation Our results showed that serum visfatin was increased in patients with MetS, especially in those with carotid plaques. Visfatin may be an inflammatory marker of MetS.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>18363885</pmid><doi>10.1111/j.1365-2265.2008.03248.x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-0664 |
| ispartof | Clinical endocrinology (Oxford), 2008-12, Vol.69 (6), p.878-884 |
| issn | 0300-0664 1365-2265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69839363 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Biological and medical sciences Carotid Artery Diseases - blood Carotid Artery Diseases - pathology Carotid Artery, Common - diagnostic imaging Carotid Artery, Common - pathology Endocrinopathies Female Fundamental and applied biological sciences. Psychology Humans Male Medical sciences Metabolic diseases Metabolic Syndrome - blood Middle Aged Miscellaneous Nicotinamide Phosphoribosyltransferase - blood Other metabolic disorders Regression Analysis Tunica Intima - diagnostic imaging Tunica Intima - pathology Tunica Media - diagnostic imaging Tunica Media - pathology Ultrasonography Vertebrates: endocrinology |
| title | Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T10%3A11%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increased%20serum%20visfatin%20in%20patients%20with%20metabolic%20syndrome%20and%20carotid%20atherosclerosis&rft.jtitle=Clinical%20endocrinology%20(Oxford)&rft.au=Zhong,%20Ming&rft.date=2008-12&rft.volume=69&rft.issue=6&rft.spage=878&rft.epage=884&rft.pages=878-884&rft.issn=0300-0664&rft.eissn=1365-2265&rft.coden=CLECAP&rft_id=info:doi/10.1111/j.1365-2265.2008.03248.x&rft_dat=%3Cproquest_cross%3E69839363%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69839363&rft_id=info:pmid/18363885&rfr_iscdi=true |